IP Library Granted Patent US 8,981,056
Granted Patent B2
US 8,981,056 · App. 13/499,356 · Granted Mar 17, 2015

Variant LovD polypeptide

Inventors: Yi Tang (San Gabriel, CA); Xue Gao (Los Angeles, CA); Xinkai Xie (Los Angeles, CA)
Assignee: The Regents of the University of California
C12N9/1029C12P7/62C12P17/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,981,056
App. No.
13/499,356
Granted
Mar 17, 2015
Kind
B2
Abstract

The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilities currently producing lovastatin can be converted to producing simvastatin and related compounds with minimal modifications.

Claims (17)

1. An isolated variant of a native LovD polypeptide, wherein the variant LovD polypeptide comprises amino acid substitutions at an amino acid residue selected from the group consisting of: A10; D12; K26; A86; A190; H161; K227; G275; V334; and L361 of SEQ ID NO: 1, wherein the variant LovD polypeptide has an improved whole cell activity at 25° C. as compared to the LovD polypeptide of SEQ ID NO:1.

2. The variant LovD polypeptide of claim 1 , wherein

the variant comprises amino substitutions at amino acid residue positions C40 and C60 of SEQ ID NO:1.

3. The variant LovD polypeptide of claim 1 or 2 , wherein the variant LovD polypeptide comprises amino acid substitutions selected from the group consisting of: A10V; D12G; K26E; C40A; C60N; A86V; H161Y; A190T; K227R; G275S; V334D; V334F; and L361M.

4. The variant LovD polypeptide of claim 1 , wherein the variant exhibits:

a decreased aggregation;

an improved thermal stability;

an improved catalytic activity;

an improved k cat /K m value; or

an improved soluble expression level.

5. A composition of matter comprising:

monacolin J;

an acyl thioester that donates an acyl moiety to the C8 hydroxyl group of monacolin J in the presence LovD acyltransferase;

a variant of LovD polypeptide comprising an amino acid substitution at:

amino acid residue positions C40 and C60; and

at least one amino acid residue position: A10; D12; K26; A86; A190; H161; K227; G275; V334; or L361 of SEQ ID NO:1, wherein the variant LovD polypeptide has an improved whole cell activity at 25° C. as compared to the LovD polypeptide of SEQ ID NO:1; and

simvastatin.

Assignments (3)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2012
From: TANG, YI; GAO, XUE; XIE, XINKAI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 028217/0711 →
CONFIRMATORY LICENSE Recorded May 15, 2012
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028208/0109 →
Continuity (2)
Provisional Application 61249894 · Oct 8, 2009
Related Publication 20120190038A1 · Jul 26, 2012